NEWS HIGHLIGHTS
Published Studies Related to Sulindac
Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. [2009.03]
Nonsteroidal anti-inflammatory drugs (NSAID) have been associated with adverse cardiovascular (CV) outcomes in cancer prevention and other clinical trials. A recent meta-analysis suggested that baseline CV risk is associated with NSAID-associated adverse CV events...
Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms. [2009]
BACKGOUND: When considering surgery for branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs) with suspected malignancy, it should be recognized that these lesions are frequently multifocal and are usually found in elderly patients with potential comorbidities that could affect the outcome of surgery. Clinical trials of chemoprevention have been conducted for a wide variety of malignancies... CONCLUSIONS: Although a larger scale randomized controlled study is needed in future, the present results suggest the promise of chemoprevention of carcinoma derived from BD-IPMNs by sulindac.
Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. [2008.11]
In a randomized, placebo-controlled, double-blind clinical trial by Meyskens et al. the combination of difluoromethylornithine and sulindac has been shown to be strikingly effective for prevention of sporadic colorectal adenomas...
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. [2008.06]
Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas... Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. [2008]
Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas... Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.
Clinical Trials Related to Sulindac
Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers [Completed]
RATIONALE: Giving healthy volunteers sulindac capsules or sulindac tablets may help doctors
learn which form of the drug may be more effective in preventing cancer.
PURPOSE: This randomized clinical trial is studying sulindac capsules to see how well they
work compared with sulindac tablets in healthy volunteers.
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer [Active, not recruiting]
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
or coming back. The use of sulindac may prevent breast cancer.
PURPOSE: This randomized phase I trial is studying the effects of sulindac, to prevent breast
cancer, in women at high risk for breast cancer.
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps [Active, not recruiting]
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,
or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not
yet known whether eflornithine and sulindac are more effective than a placebo in preventing
colorectal cancer.
PURPOSE: This randomized phase III trial is studying eflornithine and sulindac to see how
well they work compared to a placebo in preventing colorectal cancer in patients with colon
polyps.
Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients Who Have Had Surgery to Remove Benign Colorectal Polyps [Active, not recruiting]
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of eflornithine and sulindac may be an effective
way to prevent the development of colorectal cancer in patients who have had surgery to
remove benign colorectal polyps.
PURPOSE: Randomized, double-blinded, phase II trial to determine the effectiveness of
eflornithine plus sulindac compared to a placebo in preventing colorectal cancer in patients
who have had surgery to remove benign colorectal polyps.
A Randomized Study of Sulindac in Oral Premalignant Lesions [Recruiting]
The purpose of this study is to see if a drug called sulindac can prevent the development of
changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia)
or oral cancer. Sulindac is an anti-inflammatory drug that has already been tested in
people with arthritis (inflammation of a joint).
This study is being done by Memorial Sloan-Kettering Cancer Center in New York, Amrita
Institute of Medical Sciences and Research Center in Cochin, India, and Regional Cancer
Centre (RCC) in Trivandrum, India.
You have been chosen to take part in this study because you have been diagnosed with oral
intra-epithelial neoplasm (white or red patches of oral cavity). People with pre-cancerous
mouth growths are at greater risk of developing mouth cancer compared to those who do not
have such growths.
Therefore, we are asking you to take part in this study. If you decide to join, you will be
questioned by the staff in charge of this study to make sure that you meet other eligibility
criteria for participation.
|
